Six cases of rare but severe blood clots include one death and three other hospitalizations. Providers should be wary of administering standard therapy like heparin to symptomatic patients recently vaccinated with the Janssen vaccine.
Bioethicists say much can be learned from the results
March 24, 2021
Lawmakers, academics, and the research community have hotly debated the ethics of a human challenge study since the first months of the COVID-19 pandemic. Now that the United Kingdom has started dosing patients in its human challenge study, some bioethicists say this trial can show vaccine efficacy in ways the larger vaccine trials cannot.
Tested against some variants, 85% effective in preventing severe COVID-19
March 4, 2021
The Food and Drug Administration has issued an emergency use authorization for a third vaccine COVID-19 in the United States, approving Janssen Biotech’s vaccine for administration to those 18 years and older.
Bamlanivimab is a neutralizing recombinant IgG1 monoclonal antibody that connects to the receptor-binding domain of the spike protein of SARS-CoV-2. The drug blocks attachment and entry of the virus into human cells.